Inferra AI / Company / MMED
Minimed Group, Inc.
MMED · Health Care
Last earnings Sep 1, 2026
Key results
Organic revenuequarter
1.5 %
(2) $ 238 $ 234 1.5 % $ $ $ 238 $ 234 1.5 % International (2) 599 489 22.4 % 50 549 489 12.2 % Total $ 837 $ 724 15.6 % $ 50 $ $ 787 $ 724 8.7 % (1) Organic Revenue Growth measures revenue growth trends excluding the impacts of foreign currency rate fluctuations and adjustments to MiniMed s Italian payback accrual for certain prior years since 2015.
SEC original ↗Minimed Group, Inc. — Earnings release (8-K exhibit)EX-99Jun 3, 2026
Revenuequarter
$50 million
(3) The three months ended April 24, 2026 excludes $50 million of revenue adjustments related to favorable currency impact on net sales.
SEC original ↗Minimed Group, Inc. — Earnings release (8-K exhibit)EX-99Jun 3, 2026
Gross marginquarter
$480 million
Gross Profit 480 405 1,680 1,528
SEC original ↗Minimed Group, Inc. — Earnings release (8-K exhibit)EX-99Jun 3, 2026
Gross marginfull-year
$1,680 million
Gross Profit 480 405 1,680 1,528
SEC original ↗Minimed Group, Inc. — Earnings release (8-K exhibit)EX-99Jun 3, 2026
Research and developmentquarter
$99 million
Research and development expense 99 107 448 436
SEC original ↗Minimed Group, Inc. — Earnings release (8-K exhibit)EX-99Jun 3, 2026
Research and developmentfull-year
$448 million
Research and development expense 99 107 448 436
SEC original ↗Minimed Group, Inc. — Earnings release (8-K exhibit)EX-99Jun 3, 2026
AI analysis
Q4 2026 · reported Jun 3, 2026
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The quarter in charts
Guidance ladder — revenue
Delivered vs the company's guided range
EX-99 · Jun 3, 2026 Guide as stated by the company; range and midpoint computed from the stated figure.
Headline figures
| Metric | Q4 2026 | Prior qtr | Year ago |
|---|---|---|---|
| Organic revenue | 1.5 % | — | — |
| Revenue | $50 million | — | — |
| Gross margin | $480 million | — | — |
| Research and development | $99 million | — | — |
Guidance · company-stated
Direction: Initiated
“htm EX-99.1 Q4 2026 EARNINGS RELEASE Document Exhibit 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE MiniMed Delivers Strong Fourth Quarter and Full Fiscal Year 2026 Financial Results Provides Fiscal Year 2027 Outlook Continued momentum in Q4, with net sales of $837 million growing 16% as reported and 9% organic year-over-year Record annual net sales performance surpasses $3B for first time, growing 14% as reported and 8% organic Advanced global pipeline ahead of schedule with FDA clearance for MiniMed Flex TM , CE Mark for Instinct, and global launch of MiniMed Go TM Smart MDI NORTHRIDGE, Calif.”
Classified from the release's primary full-year outlook statement.
Margin
Capital allocation
Debt Supplier Financing Arrangements The Company participates in a supplier financing program that provides participating suppliers the ability to finance payment obligations from the Company with a third-party financial institution in order to receive earlier payment.
What changed vs last quarter
- Guide midpoint vs latest-quarter revenue +1574.0% computed from stated figures
Event summary
Minimed Group, Inc. Q4 2026 — (2) $ 238 $ 234 1.5 % $ $ $ 238 $ 234 1.5 % International (2) 599 489 22.4 % 50 549 489 12.2 % Total $ 837 $ 724 15.6 % $ 50 $ $ 787 $ 724 8.7 % (1) Organic Revenue Growth measures revenue growth tren…
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Initiated
Revenue: “htm EX-99.1 Q4 2026 EARNINGS RELEASE Document Exhibit 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE MiniMed Delivers Strong Fourth Quarter and Full Fiscal Year 2026 Financial Results Provides Fiscal Year 2027 Outlook Continued momentum in Q4, with net sales of $837 million growing 16% as reported and 9% organic year-over-year Record annual net sales performance surpasses $3B for first time, growing 14% as reported and 8% organic Advanced global pipeline ahead of schedule with FDA clearance for MiniMed Flex TM , CE Mark for Instinct, and global launch of MiniMed Go TM Smart MDI NORTHRIDGE, Calif.”
Revenue — Initiated (“first time”)
“htm EX-99.1 Q4 2026 EARNINGS RELEASE Document Exhibit 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE MiniMed Delivers Strong Fourth Quarter and Full Fiscal Year 2026 Financial Results Provides Fiscal Year 2027 Outlook Continued momentum in Q4, with net sales of $837 million growing 16% as reported and 9% organic year-over-year Record annual net sales performance surpasses $3B for first time, growing 14% as reported and 8% organic Advanced global pipeline ahead of schedule with FDA clearance for MiniMed Flex TM , CE Mark for Instinct, and global launch of MiniMed Go TM Smart MDI NORTHRIDGE, Calif.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Debt Supplier Financing Arrangements The Company participates in a supplier financing program that provides participating suppliers the ability to finance payment obligations from the Company with a third-party financial institution in order to receive earlier payment.
SEC original ↗Minimed Group, Inc. — 10-Q Quarterly report10-QSep 8, 2026
Revolving Credit Facility During fiscal 2026, the Company entered into a credit agreement that provides for a five year senior secured revolving credit facility (the Revolving Credit Facility ) with an aggregate available principal amount of up to $ 500 million.
SEC original ↗Minimed Group, Inc. — 10-Q Quarterly report10-QSep 8, 2026
The Revolving Credit Facility became available upon the completion of the Company s IPO on March 9, 2026, and matures in March 2031.
SEC original ↗Minimed Group, Inc. — 10-Q Quarterly report10-QSep 8, 2026
The Revolving Credit Facility contains customary representations and warranties, affirmative and negative covenants, and events of default.
SEC original ↗Minimed Group, Inc. — 10-Q Quarterly report10-QSep 8, 2026
As of July 31, 2026, no amounts were outstanding under the Revolving Credit Facility, and the Company was in compliance with all applicable covenants.
SEC original ↗Minimed Group, Inc. — 10-Q Quarterly report10-QSep 8, 2026
The assumptions used in the Black-Scholes option pricing model for the ESPP were as follows: Three Months Ended July 31, 2026 Assumptions used: Expected life (years) 0.5 Risk-free interest rate 3.96 % Volatility 33.68 % Dividend yield % Note 10.
SEC original ↗Minimed Group, Inc. — 10-Q Quarterly report10-QSep 8, 2026
Strategy & priorities
Fiscal Fourth Quarter Results Continued momentum through the second half of the fiscal year 2026, driven by Simplera TM and Instinct sensor, made by Abbott, CGM launches Worldwide net sales of $837 million grew 15.6% as reported and 8.7% organic International net sales of $599 million grew 22.4% as reported and 12.2% organic, driven by Simplera capacity expansion International New Pumps Sold (NPS) increased high-single digits sequentially U.
SEC original ↗Minimed Group, Inc. — Earnings release (8-K exhibit)EX-99Jun 3, 2026
GAAP, we present in this earnings press release certain financial measures that facilitate management s review of the operational performance of MiniMed and serve as a basis for strategic planning however, such financial measures are not presented in our financial statements prepared in accordance with U.
SEC original ↗Minimed Group, Inc. — Earnings release (8-K exhibit)EX-99Jun 3, 2026
( MiniMed or the Company ) is a medical technology company focused on the development, manufacture, and commercialization of insulin pumps, continuous glucose monitoring ( CGM ) systems, related consumables, smart pens, and digital health solutions for the management of Type 1 and Type 2 diabetes.
SEC original ↗Minimed Group, Inc. — 10-Q Quarterly report10-QSep 8, 2026
In some actions, the enforcement agencies or private claimants seek significant monetary damages and/or royalty payments, as well as other civil or criminal remedies (including injunctions barring or restricting the sale of products that are the subject of the proceeding, placing restrictions on competitive strategies or practices, or unwinding consummated transactions), any or all of which could have a material adverse impact on the Company s consolidated earnings, financial position, and/or cash flows.
SEC original ↗Minimed Group, Inc. — 10-Q Quarterly report10-QSep 8, 2026
Segment Information The Company derives its revenue primarily from the sale of products focused on diabetes management, including insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens.
SEC original ↗Minimed Group, Inc. — 10-Q Quarterly report10-QSep 8, 2026
Risks & headwinds
With respect to intellectual property disputes, the Company is involved in or at risk for litigation relating to patents, trademarks, copyrights, trade secrets, and other intellectual property ( IP ) rights, and licenses, acquisitions or other agreements relating to such rights.
SEC original ↗Minimed Group, Inc. — 10-Q Quarterly report10-QSep 8, 2026
This litigation includes, but is not limited to, alleged infringement, misappropriation, or other violation of IP rights, or breach of obligations related to IP rights, or other claims asserted by competitors, individuals, or, consistent with a growing trend across technology-intensive industries, other entities created specifically to fund IP litigation.
SEC original ↗Minimed Group, Inc. — 10-Q Quarterly report10-QSep 8, 2026
With respect to commercial disputes, antitrust and competition issues have gained increased prominence, enforcement and private litigation have increased globally, and the Company is involved in or at risk for antitrust litigation, investigations or enforcement actions regarding a range of commercial activities, including challenges to mergers and acquisition transactions, joint ventures, co-development or co-marketing arrangements, contracting practices, distribution agreements and employment agreements.
SEC original ↗Minimed Group, Inc. — 10-Q Quarterly report10-QSep 8, 2026
Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice.
SEC original ↗Minimed Group, Inc. — 10-Q Quarterly report10-QSep 8, 2026
The Company classifies certain specified litigation charges and gains related to significant legal matters as certain litigation charges, net in the condensed consolidated statements of operations.
SEC original ↗Minimed Group, Inc. — 10-Q Quarterly report10-QSep 8, 2026
During the three months ended July 31, 2026, and July 25, 2025, the Company recognized a reversal of a previously accrued litigation charges of $ 2 million and a charge of $ 17 million, respectively.
SEC original ↗Minimed Group, Inc. — 10-Q Quarterly report10-QSep 8, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
16 documents- Q3 2026
- 8-KMMED
Oct 16, 2026
- 8-KMMED
Oct 13, 2026
- Q2 2026
- 10-QMMED
Sep 8, 2026
- 8-KMMED
Sep 1, 2026
- EX-99MMED
Sep 1, 2026
- 8-KMMED
Aug 5, 2026
- Q1 2026
- 8-KMMED
Jun 29, 2026
- 10-KMMED
Jun 29, 2026
- 8-KMMED
Jun 3, 2026
- EX-99MMED
Jun 3, 2026
- 8-KMMED
May 18, 2026
- 8-KMMED
Apr 27, 2026
- 10-QMMED
Apr 17, 2026
- Q4 2025
- 8-KMMED
Mar 27, 2026
- 8-KMMED
Mar 25, 2026
- 8-KMMED
Mar 9, 2026
Earnings releases
2 documentsPresentations
0 documentsNo presentations for Minimed Group, Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Minimed Group, Inc. are held in this edition of the library.
Mentioned by
2 companiesOther tracked companies whose held documents mention Minimed Group, Inc. by name or ticker. A mention is counted once per document, from the document text the library holds.
“to $0.72 per share, implying annual $2.88 per share; 49 th consecutive year of… …from the MiniMed Blackstone payment and 80 basis points from tariffs. Q4 GAAP net income and diluted earnings per share (EPS) were $1.243 billion and $0.96, respectively”
“y increases FY24 organic revenue growth and EPS guidance • Commenced U.S. launches of the MiniMed™ 780G system with Guardian™ 4 sensor in Diabetes and the Micra™… …Interventions businesses within our Medical Surgical Portfolio. The prior year include”
See also the earnings calendar for every tracked company’s next earnings date.